Medical devices, healthcare technology and the business of care
PMA approval · P170019

FoundationOne CDx

Foundation Medicine, Inc. · Decision date Nov 30, 2017

FDA DECISIONP170019

What did the FDA approve?

FDA records P170019 as an original PMA application. The recorded decision is approval, dated Nov 30, 2017.

FDA approval order statement

Approval for the FoundationOne CDx (F1CDx). This device is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The F1CDx assay is a single-site assay performed at Foundation Medicine, Inc.Table 1: Companion diagnostic indicationsIndication: Non-small cell lung cancer (NSCLC). - Biomarker: EGFR exon 19 deletions and EGFR exon 21 L858R alterations. Therapy: Gilotrif (afatinib), Iressa (gefitinib), or Tarceva (erlotinib). - Biomarker: EGFR exon 20 T790M alterations. Therapy: Tagrisso (osimertinib). - Biomarker: ALK rearrangements. Therapy: Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib). - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) in combination with Mekinist (trametinib).Indication: Melanoma. - Biomarker: BRAF V600E. Therapy: Tafinlar (dabrafenib) or Zelboraf (vemurafenib) - Biomarker: BRAF V600E and V600K. Therapy: Mekinist (trametinib) or Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib).Indication: Breast cancer. Biomarker: ERBB2 (HER2) amplification. Therapy: Herceptin (trastuzumab), Kadcyla (ado-trastuzumab-emtansine), orPerjeta (pertuzumab).Indication: Colorectal cancer. - Biomarker: KRAS wild-type (absence of mutations in codons 12 and 13). Therapy: Erbitux (cetuximab) - Biomarker: KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4). Therapy: Vectibix (panitumumab)Indication: Ovarian cancer. Biomarker: BRCA1/2 alterations. Therapy: Rubraca (rucaparib)
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Nov 30, 2017

FDA source record

Regulatory record facts

Identifier
P170019
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Nov 30, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170019 received

    Application receipt date recorded by FDA.

  2. P170019 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P170019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170019

Product / regulatory recordCompanyPathwayDecision dateSource
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Foundation Medicine, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Summer St., Boston, MA, 02210

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records